2. Peptides
  3. Peptide and Derivatives
  4. Peptides for Drug Delivery
  5. Cell-penetrating Peptides
  6. (Arg)9 acetate

(Arg)9 acetate  (Synonyms: Nona-L-arginine acetate; Peptide R9 acetate)

Cat. No.: HY-P0133B Purity: 99.89%
COA Handling Instructions

Molarity Calculator

(Arg)9 (Nona-L-arginine) acetate is a cell-penetrating peptide (CPP) made up of 9 arginine residues. (Arg)9 acetate has neuroprotective property, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

(Arg)9 acetate Chemical Structure

(Arg)9 acetate Chemical Structure

Size Price Stock Quantity
1 mg USD 110 In-stock
5 mg USD 250 In-stock
10 mg USD 360 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of (Arg)9 acetate:

(Arg)9 acetate Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE (Arg)9 acetate

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

(Arg)9 (Nona-L-arginine) acetate is a cell-penetrating peptide (CPP) made up of 9 arginine residues. (Arg)9 acetate has neuroprotective property, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model[1][2].

IC50 & Target

IC50: 0.78 μM (neuroprotection)[1]
In Vitro

(Arg)9 (Nona-L-arginine; 5-10 μM) acetate provides significant neuroprotection in a dose–response manner following glutamic acid exposure (IC50=0.78 μM). Following kainic acid exposure, (Arg)9 acetate is neuroprotective, but less effective than in the glutamic acid model (IC50=0.81 μM). (Arg)9 acetate also shows neuroprotection following in vitro ischemia (IC50=6 μM)[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

(Arg)9 acetate Related Antibodies
In Vivo

(Arg)9 (Nona-L-arginine; 1 μM/kg (600  μL); i.v.; once, for 30min; male Sprague–Dawley ratspermanent middle cerebral artery stroke model) acetate shows neuroprotective effects and reduces infarct volume[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Sprague–Dawley rats (270 to 320 g) permanent middle cerebral artery stroke model[2]
Dosage: 1 μM/kg (600  μL)
Administration: Intravenous injection; once, over 5 minutes
Result: Reduced significantiy 20% in infarct volume.
Molecular Weight

1483.74

Formula

C56H114N36O12
Appearance

Solid

Color

White to off-white

Sequence Shortening

RRRRRRRRR
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Sealed storage, away from moisture and light, under nitrogen

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

Solvent & Solubility
In Vitro: 

H2O : ≥ 50 mg/mL (33.70 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.6740 mL 3.3699 mL 6.7397 mL
5 mM 0.1348 mL 0.6740 mL 1.3479 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 100 mg/mL (67.40 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation

Purity: 99.89%

COA (242 KB) RP-HPLC (186 KB) MS (70 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O 1 mM 0.6740 mL 3.3699 mL 6.7397 mL 16.8493 mL
5 mM 0.1348 mL 0.6740 mL 1.3479 mL 3.3699 mL
10 mM 0.0674 mL 0.3370 mL 0.6740 mL 1.6849 mL
15 mM 0.0449 mL 0.2247 mL 0.4493 mL 1.1233 mL
20 mM 0.0337 mL 0.1685 mL 0.3370 mL 0.8425 mL
25 mM 0.0270 mL 0.1348 mL 0.2696 mL 0.6740 mL
30 mM 0.0225 mL 0.1123 mL 0.2247 mL 0.5616 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

(Arg)9 acetate Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

(Arg)9Nona-L-argininePeptide R9Peptide R 9Peptide R-9Otherscell-penetrating peptideneuroprotective propertyarginineinfarct volumeInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
(Arg)9 acetate
Cat. No.:
HY-P0133B
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.